ArticleEuropean journal of haematology2023

Cost-effectiveness of recombinant factor VIII Fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia A without inhibitors in the UK.

Nana Kragh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.